Physician profile
Priya Singh
NPI 1265502876
$2,867.02
in general payments reported to CMS, 2019-2025
29 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $979 · 2024: $862 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.20 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $450.54 | 2023-2025 | |
| Janssen Biotech, INC. | $332.52 | 2023-2025 | Rybrevant, Carvykti, Imbruvica |
| Celgene Corporation | $252.83 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $219.49 | 2023-2025 | Opdivo, Opdualag |
| Pfizer INC. | $184.02 | 2022-2025 | |
| Astellas Pharma US INC | $171.01 | 2023-2025 | Xospata, Vyloy, Xtandi |
| Abbvie INC. | $159.85 | 2024-2025 | |
| Eisai INC. | $149.37 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.27 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $79.56 | 2023-2024 | Keytruda, Welireg |
| Regeneron Healthcare Solutions, INC. | $78.52 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $77.59 | 2022-2025 | Zejula, Jemperli |
| Springworks Therapeutics, INC. | $76.78 | 2024-2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $64.02 | 2023-2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $63.23 | 2022-2023 | Imbruvica |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $53.40 | 2024-2025 | Opzelura, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $44.82 | 2022-2024 | Imfinzi |
| Stemline Therapeutics INC. | $30.54 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $28.42 | 2023 | Xpovio |
| Puma Biotechnology, INC. | $26.73 | 2024 | |
| Recordati_rare_diseases_inc. | $26.68 | 2025 | Sylvant |
| Adaptive Biotechnologies Corporation | $26.55 | 2023 | Clonoseq |
| Amgen INC. | $26.46 | 2023 | Kyprolis, Blincyto |
| Tempus Ai, INC | $26.22 | 2024 | |
| Seagen INC. | $25.26 | 2023 | Tukysa |
| Ipsen Biopharmaceuticals, INC | $25.12 | 2023 | Tazverik |
| Iovance Biotherapeutics, INC. | $23.44 | 2025 | Amtagvi |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Lilly USA, LLC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.